Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.02 −5.71%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Revenue to profit Twelve months to 30 September 2026

It lost $7.0M on $3.1M of revenue: $226.87 for every $100. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue0.0100.0%
Cost of revenue0.0−82.1%
Gross profit0.017.9%
Research & development0.0−55.0%
Selling, general & admin0.0−199.0%
Other operating costs0.0−1.0%
Operating income0.0−237.1%
Other income, net0.010.2%
Net income0.0−226.9%
Revenue, operating income and net income, four quartersRevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$0.0B$0.0B$0.0B$0.0B
Operating income$0.0B$0.0B$0.0B$0.0B
Net income$0.0B$0.0B$0.0B$0.0B
Net margin (right axis)−238.3%−191.5%−200.5%−226.9%
Sep '26 From the 10-Q filed 13 Nov Jun '26 Mar '26 Dec '25 Older periods
Revenue
3.09 3.80 3.81 3.09

+8 more TTM periods

Cost of Revenue
2.54 3.18 2.81 2.32
Gross Profit
0.55 0.62 0.99 0.77
R&D Expenses
1.70 1.84 2.14 2.15
SG&A Expenses
6.14 6.17 5.92 5.76
Operating Income
(7.32) (7.43) (7.11) (7.19)
Non-operating Income/Expense
0.30 (0.20) (0.20) (0.17)
Non-operating Interest Expenses
— 0.45 0.45 0.46
EBT
(7.00) (7.62) (7.29) (7.36)
Income after Tax
(7.00) (7.62) (7.29) (7.36)
Net Income Common
(7.00) (7.62) (7.29) (7.36)
EPS (Basic)
(0.21) (0.23) (0.23) (0.25)
EPS (Diluted)
(0.21) (0.23) (0.23) (0.25)
Shares (Basic, Weighted)
35.94 34.99 33.41 31.78
Shares (Diluted, Weighted)
35.94 34.99 33.41 31.78
Gross Margin
17.85% 16.24% 26.09% 24.93%
EBIT Margin
(237.12%) (195.47%) (186.65%) (232.75%)
EBT margin
(226.87%) (200.46%) (191.50%) (238.32%)
Net Profit Margin
(226.87%) (200.46%) (191.50%) (238.32%)
Free Cash Flow Margin
(227.93%) (194.73%) (150.11%) (184.52%)
EBITDA
— (7.41) (7.08) (7.17)
EBIT
(7.32) (7.43) (7.11) (7.19)
EPS (Diluted, from Cont. Ops)
(0.19) (0.21) (0.21) (0.23)
EPS (Diluted, Consolidated)
(0.19) (0.21) (0.21) (0.23)
EPS (Basic, Consolidated)
(0.19) (0.21) (0.21) (0.23)
Shares (Diluted, Average)
34.57 33.62 32.04 30.41
EPS (Basic, from Continuous Ops)
(0.19) (0.21) (0.21) (0.23)
Income from Continuous Operations
(7.00) (7.62) (7.29) (7.36)
Consolidated Net Income/Loss
(7.00) (7.62) (7.29) (7.36)
EBITDA Margin
0.00% (194.86%) (185.95%) (231.96%)
Operating Cash Flow Margin
(227.93%) (194.73%) (150.11%) (184.52%)

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 13 Nov 2026